Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Neurogene (NGNE) over the last 3 years, with Q3 2025 value amounting to -$501000.0.

  • Neurogene's Change in Account Payables fell 162758.62% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$198000.0, marking a year-over-year increase of 6063.62%. This contributed to the annual value of -$77000.0 for FY2024, which is 11154.42% down from last year.
  • As of Q3 2025, Neurogene's Change in Account Payables stood at -$501000.0, which was down 162758.62% from -$975000.0 recorded in Q2 2025.
  • Over the past 5 years, Neurogene's Change in Account Payables peaked at $1.7 million during Q1 2025, and registered a low of -$975000.0 during Q2 2025.
  • Moreover, its 3-year median value for Change in Account Payables was $27000.0 (2023), whereas its average is $73454.5.
  • Over the last 5 years, Neurogene's Change in Account Payables had its largest YoY gain of 115481.48% in 2025, and its largest YoY loss of 162758.62% in 2025.
  • Over the past 3 years, Neurogene's Change in Account Payables (Quarter) stood at -$842000.0 in 2023, then skyrocketed by 50.59% to -$416000.0 in 2024, then fell by 20.43% to -$501000.0 in 2025.
  • Its last three reported values are -$501000.0 in Q3 2025, -$975000.0 for Q2 2025, and $1.7 million during Q1 2025.